Rowan University

Rowan Digital Works
Henry M. Rowan College of Engineering Faculty
Scholarship

Henry M. Rowan College of Engineering

2-2-2021

Novel Guidewire Design and Coating for Continuous Delivery of
Adenosine During Interventional Procedures.
Mervyn B Forman
Erik Brewer
Rowan University, brewere@rowan.edu

Zachary R Brown
Elizabeth V Menshikova
Anthony M. Lowman
Rowan University, lowman@rowan.edu

See next page for additional authors

Follow this and additional works at: https://rdw.rowan.edu/engineering_facpub
Digital
Part of the Biomedical Engineering and Bioengineering Commons
Commons
Network

Recommended Citation

Logo
Forman MB, Brewer EC, Brown ZR, Menshikova EV, Lowman AM, Jackson EK, Brewer. Novel Guidewire
Design and Coating for Continuous Delivery of Adenosine During Interventional Procedures. J Am Heart
Assoc. 2021 Feb 2;10(3):e019275. doi: 10.1161/JAHA.120.019275. Epub 2021 Jan 26. Erratum in: J Am
Heart Assoc. 2021 Feb 16;10(4):e014656.

This Article is brought to you for free and open access by the Henry M. Rowan College of Engineering at Rowan
Digital Works. It has been accepted for inclusion in Henry M. Rowan College of Engineering Faculty Scholarship by
an authorized administrator of Rowan Digital Works.

Authors
Mervyn B Forman, Erik Brewer, Zachary R Brown, Elizabeth V Menshikova, Anthony M. Lowman, and Edwin
K Jackson

This article is available at Rowan Digital Works: https://rdw.rowan.edu/engineering_facpub/129

Journal of the American Heart Association
ORIGINAL RESEARCH

Novel Guidewire Design and Coating for
Continuous Delivery of Adenosine During
Interventional Procedures
Mervyn B. Forman, MD, PhD; Erik C. Brewer, PhD; Zachary R. Brown, PhD; Elizabeth V. Menshikova, PhD;
Anthony M. Lowman, PhD; Edwin K. Jackson , PhD
BACKGROUND: The “no-reflow phenomenon” compromises percutaneous coronary intervention outcomes. There is an unmet
need for a device that prevents no-reflow phenomenon. Our goal was to develop a guidewire platform comprising a nondisruptive hydrophilic coating that allows continuous delivery of adenosine throughout a percutaneous coronary intervention.
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METHODS AND RESULTS: We developed a guidewire with spaced coils to increase surface area for drug loading. Guidewires
were plasma treated to attach hydroxyl groups to metal surfaces, and a methoxy–polyethylene glycol–silanol primer layer was
covalently linked to hydroxyl groups. Using polyvinyl alcohol, polyvinyl pyrrolidone, and polyvinyl acetate, a drug layer containing jet-milled adenosine was hydrogen-bonded to the polyethylene glycol–silanol layer and coated with an outer diffusive
barrier layer. Coatings were processed with a freeze/thaw curing method. In vitro release studies were conducted followed
by in vivo evaluation in pigs. Coating quality, performance, and stability with sterilization were also evaluated. Antiplatelet
properties of the guidewire were also determined. Elution studies with adenosine-containing guidewires showed curvilinear
and complete release of adenosine over 60 minutes. Porcine studies demonstrated that upon insertion into a coronary artery,
adenosine-releasing guidewires induced immediate and robust increases (2.6-fold) in coronary blood flow velocity, which
were sustained for ≈30 minutes without systemic hemodynamic effects or arrhythmias. Adenosine-loaded wires prevented
and reversed coronary vasoconstriction induced by acetylcholine. The wires significantly inhibited platelet aggregation by
>80% in vitro. Guidewires passed bench testing for lubricity, adherence, integrity, and tracking.
CONCLUSIONS: Our novel drug-releasing guidewire platform represents a unique approach to prevent/treat no-reflow phenomenon during percutaneous coronary intervention.
Key Words: adenosine ■ cardiac guidewire ■ no-reflow phenomenon ■ percutaneous coronary intervention

I

n spite of numerous advances in pharmacologic modalities to modify associated risk factors, coronary
artery disease remains a major cause of morbidity
and mortality.1 Because of the advent of drug-eluting
stents and technical advances in equipment, percutaneous coronary intervention (PCI) has rapidly evolved
as the most common modality to treat coronary artery disease.2 Unfortunately, however, microvascular
obstruction (MVO) and the “no-reflow phenomenon”
(NRF) remain important obstacles to achieving optimal tissue perfusion after PCI. MVO and NRF are

particularly problematic in anterior ST-segment–elevation myocardial infarction (STEMI) and saphenous vein
grafts.3–5 Magnetic resonance imaging studies emphasize the role of MVO as an independent risk factor for
major cardiovascular events with a greater predictive
power than ejection fraction or infarct size.6–8
The mechanisms responsible for MVO are complex
and multifactorial and include embolization by atheromatous and thrombotic debris, release of potent
vasoconstrictive substances, platelet aggregation, activation of immune cells resulting in leukocyte plugging
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CLINICAL PERSPECTIVE
What Is New?

• Microvascular obstruction and the no-reflow
phenomenon are major barriers that preclude
optimal outcomes in patients undergoing percutaneous coronary interventions.
• Drawing upon numerous technologies, we have
developed an adenosine-releasing guidewire
that has the potential to prevent and treat microvascular obstruction and no-reflow phenomenon, thus greatly improving patient outcomes.

What Are the Clinical Implications?

• Our novel adenosine-releasing guidewire provides for an autonomous adenosine-releasing system that performs without thought or
planning.
• Therefore, by using Adenowires, the interventionalist can protect patients from microvascular obstruction and the no-reflow phenomenon
without altering their workflow.
• Adenowires have considerable translational
potential.
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Nonstandard Abbreviations and Acronyms
CFV
MVO
NRF
PEG
PRP
PVA
PVAc
PVP
SS

coronary flow velocity
microvascular obstruction
no-reflow phenomenon
polyethylene glycol
platelet-rich plasma
polyvinyl alcohol
polyvinyl acetate
polyvinyl pyrrolidone
sum of squares

oxygen free radicals.4,5 Indeed, case reports suggest
that intracoronary adenosine does reverse MVO/
NRF.13 While the majority of experimental and clinical studies demonstrate beneficial effects of continuous infusions of adenosine on enhancing myocardial
salvage and improving microvascular flow, it is likely
that the full therapeutic potential of adenosine is compromised because of adenosine’s ultra-short half-life
(≈1 second) in blood and because of the dilution of the
administered adenosine when delivered via a guiding
or balloon catheter.4,5 We therefore conceived the idea
that since the guidewire is the first mandatory device
placed for PCI, incorporation of adenosine on the
guidewire would allow immediate and targeted continuous release of adenosine throughout the procedure
and improve post-PCI perfusion.
In our initial attempt, we developed a nontoxic pentameric form of adenosine using polyurethane technology.14 While cumulative adenosine release and modest
in vivo coronary vasodilatation was demonstrated on
micro-machined guidewires, it became apparent that
it would not be an acceptable solution for 2 reasons.
First, the surface area of the guidewire was small, resulting in an insufficient drug load. Second, the coating
was degradable and exhibited poor lubricity, durability,
and adhesive properties compared with guidewires
with hydrophilic coatings. We therefore changed directions to address the inadequacies of the first iteration.
This paper describes in detail an innovative device
platform to include a new guidewire design and novel
hydrogel coating that allows sufficient quantities of adenosine to be released over a typical PCI procedure to
produce robust vasodilatation and reversal of severe
pharmacologically induced vasoconstriction in the
porcine model. Confirmation of coating lubricity, adherence, and durability and guidewire performance of
the “Adenowire” is also presented.

METHODS
and endothelial cell disruption of microvessels.3–5
Since current vascular devices are only partially effective in preventing vascular and organ damage and do
not reduce mortality, there is a dire need to develop
new technologies to improve outcomes after PCI.9–12
Adenosine is an endogenous nucleoside that activates 4 well-characterized receptors. Adenosine
preserves microcirculatory flow by (1) preventing and
reversing constriction of the coronary microcirculation induced by numerous vasoconstrictors including
thromboxane A2, platelet-activating factor, angiotensin
II, norepinephrine, and endothelin-1; (2) inhibiting activation of leukocytes; (3) inhibiting platelet activation;
(4) blocking release of myeloperoxidase; (5) preventing calcium overload; and (6) reducing production of

For data and for additional information on analytic
methods or study materials, contact E.K. Jackson at
edj@pitt.edu.

Guidewire Design
In preliminary studies, we determined that although
micro-machined guidewires could elute adenosine,
use of traditional guidewire designs, because of limited
surface area, could not provide an optimal drug load.14
In collaboration with 2 leading wire manufacturers
(Asahi-Intecc, Justin, CA; and Lake Region Medical,
Chaska, MN), we successively modified their popular
wire designs by increasing the coil spacing in the distal
15 cm of the wire to 0.005 inches while maintaining the
wire performance and characteristics of the predicated
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device. Detailed drawings of the 2 wires are shown in
Figure 1. The wires are made of stainless steel and contain a coil spacing zone of 150 mm, with slight variation
in the placement of the radiopaque tungsten-platinum
marker. The coil-wound section was left uncoated,
with the solid mandrel covered with proprietary Teflon.
Mechanical testing requirements of both wires (tensile
testing of all joints, torque strength, torqueability, tip
flexion, and biocompatibility) met all the acceptance
criteria and were similar to the predicate device.

Hydrogel-Drug Coating
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The proposed chemical reactions involved in coating
the wire are illustrated in Figures 2–5. The materials
used for coating were polyvinyl alcohol (PVA; Mowiol
28-99, MW 145 kDa; EMO Millipore, Billerica, MA), polyvinyl acetate (PVAc; Kollicoat SR 30D; Sigma-Aldrich,
St. Louis, MO), polyvinyl pyrrolidone (PVP; Providone
K-30; Spectrum Chemical, New Brunswick, NJ),
methoxy–polyethylene glycol (PEG)-silane (Jenkem
Technology, Plano, TX), and adenosine (SigmaAldrich). Coronary guidewires were cleaned in the distal 20- to 30-cm coiled region with an ultrasonic probe
for 5 minutes in ethanol followed by deionized water
for 5 minutes and dried via a nitrogen gas line as previously described.15–17 The wires were then subjected to
oxygen plasma treatment for 2 minutes using a commercial device (PE25-JW; Plasma Etch, Carson City,

Guidewire for Continuous Delivery of Adenosine

NV), which resulted in deposition of hydroxyl groups
on the surface (Figure 2, reaction 1).18 A primer layer
was then deposited on the wire utilizing methoxyPEG-silane (MW, 20 kDa). In this regard, a solution
of methoxy-PEG-silane (40 mg/mL) was prepared in
an ethanol/water solution (95/5 w/w) that was titrated
to a pH of 5.0 with glacial acetic acid. After 30 minutes to allow the methoxy-PEG-silane to hydrolyze
(Figure 3, reaction 2), the wires were dipped in the hydrolyzed methoxy-PEG-silane mixture (now methoxyPEG-silanol solution) for 1 hour and cured at 70°C for
90 minutes in a vacuum oven set at <0.1 bar. As shown
in Figure 4 (reaction 3), the silanol groups covalently
bond to the hydroxyl groups on the stainless steel and
crosslink with neighboring silanol moieties to form a
robust primer layer.
Next, the inner drug layer was prepared. To accomplish this, a 20% w/w solution of PVA/PVP (99:1 mass
ratio) in deionized water was prepared and autoclaved
for 1 hour while stirring. This yielded a supersaturated
solution that was homogeneous and free of bubbles.
Using a water bath, the temperature of the PVA/PVP
solution was maintained at 65°C. A 25% concentration
of adenosine was required in the drug layer to provide
a sufficient drug load on the wire. However, adenosine
has poor solubility in water (80 mg/mL), making it difficult to achieve this concentration of adenosine in the
drug layer. Moreover, commercial adenosine has a mean
particle size of 55 μm which would have compromised

Figure 1. The diagrams illustrate 2 types of 0.014-inch stainless steel guidewires used in the present study.
Adenosine-releasing guidewires are redesigns of 2 popular commercially approved wires (0.014-inch stainless steel), which have
been modified by increasing the coil spacing to 0.005 inches in the distal 15 cm to accommodate the hydrophilic-drug polymer. In (A)
the radiopaque platinum-tungsten portion is incorporated in the mandrel and in (B) is in the 3 cm of tightly wound coil at the tip. C, A
micrograph of the redesigned 0.005-inch coils before coating. D, Micrograph of the 0.005-inch coils after coating with the polyethylene
glycol–silane primer layer, adenosine-loaded hydrogel layer and diffusion-barrier layer. PTFE indicates polytetrafluoroethylene.
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Figure 2. Reaction 1: guidewires were initially exposed to
plasma treatment to create OH groups on the stainless steel
surface.
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the lubricity of the wire. To overcome these barriers,
we utilized a 2-pass jet-milling process to reduce the
solid-phase adenosine particles to <5 μm. Micronized
adenosine was mixed in deionized water, sonicated for
15 minutes, and then added to the PVA/PVP mixture,
and the PVA/PVP/adenosine mixture was stirred until a
homogeneous mixture was obtained. This resulted in a
mixture that contained 7.5% PVA, 67.5% water, and 25%
adenosine, which was kept at 65°C for the duration of
the coating process. Next, the guidewire coated with the
PEG-silanol primer was coated with the adenosine-containing hydrogel. Multiple hydroxyl groups in the hydrogel
form hydrogen bonds with multiple ether, carbonyl and
amine groups in the primer, thus creating an extensive
network of hydrogen bonds between the drug-containing hydrogel layer and the primer layer (Figure 5, reaction
4). This results in a stable attachment of the drug layer
with the wire surface. Laser diffraction and optical microscopy demonstrated stable particle sizes of the jetmilled adenosine even after 1 week in the hydrogel.
The outer barrier layer was produced using PVA
with PVAc in a ratio of 1:3 (w/w). A 20% solution of
PVA without PVP was prepared as described above.
Commercially available PVAc packaged as a 30% dispersion with stabilizers and excipients was added to
the PVA solution and mechanically mixed at 65°C to
achieve a homogeneous solution. The final solution,
consisting of 5% PVA, 80% deionized water and 15%
PVAc, was left at room temperature.
The wires were coated using a mechanical dipper
(Precision Dip Coater QPI-168; Qualtech, Denver, CO),
with insertion and withdrawal parameters set to obtain

Figure 3. Reaction 2: methoxy–polyethylene glycol (PEG)silane was treated with acid to hydrolyze the ester linkages,
thus producing PEG-silanols with exposed OH groups.

a total polymer weight of ≈45 mg per 10-cm length of
wire. For the drug layer, an insertion rate of 200 mm/
min, dwell time of 10 seconds, and withdrawal rate of
40 mm/min was employed. After applying the drug
layer, the wire was immediately flash frozen in liquid nitrogen and subjected to a 60-minute freeze/thaw cycle:
45 minutes at −20°C, followed by thawing at room temperature. This freeze/thaw cycle was then repeated
to harden the gel. The wire was then coated with the
barrier layer using a withdrawal rate of 500 mm/s, after
which the wire was subjected to a further 2 freeze/thaw
cycles. The final product contained a total polymer
weight per 10-cm length of wire of ≈40 to 45 mg with a
drug load of 2.7±0.2 mg of adenosine per 10-cm length
of wire.

In Vitro Release Studies
These studies (n=6) were performed in 0.9% saline
rather than in plasma or blood because adenosine
has a short half-life (seconds) in the latter 2 media,
making detection difficult. Tubes containing 15 mL of
saline were maintained at 37°C, and 10 cm of the
spaced coiled section of the guidewire was placed
serially in tubes for 0 to 5, 5 to 10, 10 to 20, 20 to
30, 30 to 40, 40 to 50, and 50 to 60 minutes. Onemilliliter samples were then taken from the tubes
to measure the concentration of adenosine by
spectrophotometry.19
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Figure 4. Reaction 3: PEG-silanols condensed with OH
groups both on the wire and on neighboring silanols to form
a polymerized primer layer.

Guidewire for Continuous Delivery of Adenosine

Figure 5. Reaction 4: grafting of the polyvinyl alcohol/
polyvinyl pyrrolidone/polyvinyl acetate hydrogel to the primer
layer is achieved via hydrogen bonding interactions between
the carbonyl, ether and amine groups of polyethylene glycol
and the OH groups of polyvinyl alcohol.

Animal Studies
All porcine studies were approved by Institutional
Animal Care and the Committee of Synchrony Labs
LLC (Durham, NC). Yucatán mini pigs (male and
female, 25–30 kg, 6 months of age) were premedicated with Telazol (5 mg/kg). Anesthesia was maintained with 1% isoflurane and supplemental oxygen
to maintain a pH of 7.4±0.6. Animals received aspirin 300 mg orally for 3 days before the study and
were anticoagulated throughout the procedure with
heparin (150 units/kg) to maintain activated clotting
time >300. Heart rate, ECG changes, and blood
pressure were monitored continuously using leads I,
aVF, and aVL with a 6 F sheath in the left femoral artery. Another sheath was placed in the right femoral
artery for coronary intubation of the left main vessel using a 6 F HS guide catheter. Coronary blood
flow velocity (CFV) was measured using a 0.014-inch
Doppler flow wire (Combowire; Volcano Corporation,
Rancho Cordova, CA) and dedicated software. CFV
was measured as a continuous average pulse wave
velocity over 4 seconds, and mean values were recorded every 60 seconds.
Two experimental protocols were employed. In
the first protocol (n=8), we assessed the efficacy and

duration of vasodilatation induced by the guidewire
under basal conditions. The Combowire was positioned in either the proximal circumflex or left anterior
descending coronary artery (LAD), and baseline CFV
was measured after obtaining an optimal velocity
tracing. Care was taken to ensure that the Doppler
wire remained in the same position throughout the
experiment. An adenosine-loaded guidewire was
positioned in the distal circumflex coronary artery or
LAD, and heart rate, blood pressure, and CFV was
measured serially every minute for 30 minutes. The
drug-coated wire was removed, and CFV was measured until it had returned to baseline. Serial coronary angiography was performed at baseline, after
Combowire placement and after removal of the medicated guidewire.
In the second protocol, we evaluated the ability
of the wire to prevent and reverse intense vasoconstriction induced by intracoronary administration
of acetylcholine. Release of numerous potent vasoconstrictors plays a key role in the pathogenesis
of NRF. Acetylcholine is a powerful vasoconstrictor in the porcine model via direct muscarinic activation of smooth muscle cells in small coronary
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arteries resulting in NRF.20 A Transit infusion catheter
(Codman, Roynham, MA) was placed in the proximal LAD for the drug infusion. Acetylcholine doses
of 0.3 to 1.0 mg/min were infused into the LAD for
20 to 30 minutes. Preliminary studies showed that
this results in an ≈80% reduction in CFV. In some
studies, acetylcholine was commenced initially and
after a >50% decrease in CFV was observed, an adenosine-loaded guidewire was rapidly inserted into
the distal vessel for 15 to 20 minutes. These studies
were designed to determine if the wire could reverse
the NRF. In other experiments, we evaluated whether
an adenosine-releasing wire could prevent the NRF
by placing the adenosine-loaded wire initially into the
LAD. Once an increase in CFV had occurred, an acetylcholine infusion was begun for 20 to 30 minutes.
In some studies, the wire was removed at 20 minutes and the acetylcholine infusion continued, while
in others the acetylcholine infusion was terminated
and the wire was left in place for a further 10 minutes
in the vessel.

Evaluation of Wire Performance, Coating
Quality, and Integrity
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Because guidewires are used to place a device
into coronary vessels, it is essential that they easily
negotiate a tortuous vasculature to facilitate placement of devices without inducing vascular damage.
To assess guidewire lubricity, a 2-dimensional coronary model system (ASTM 2394) and a MSI IDTE
3000 device with dedicated software were utilized
(Machine Solutions, Flagstaff, AZ). A 6 F coronary
guide catheter was introduced 3 cm into the mock
vessel. The wire was inserted through a hemostatic
valve into the catheter and tracked for 3 cycles in
the model for a distance of 38 cm. A proximal load
cell with an encoder was used to measure the force
applied to deliver and retract the guidewire and the
distance in and out of the model. Microscopic images were obtained at baseline, after the track test
and after hydration for 1 hour. Wire performance was
determined in vitro and in vivo and included the ability to navigate the model or vessel, torqueability, and
tip flexibility.

Platelet Aggregation Studies
Human venous blood was obtained from 4 healthy
donors who had not taken any medications known
to influence platelet function for at least 2 weeks
before the study and as described by Gurbel and
coworkers.21 Procedures were performed according to institutional research committee standards,
and informed consent was obtained. Venous blood
samples were collected into 3.2% trisodium citrate Vacutainer tubes. After 15 minutes, the tubes
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were centrifuged at 200g for 10 minutes at room
temperature to recover platelet-rich plasma (PRP).
Platelet-poor plasma was then obtained by centrifuging PRP at 1500g for 10 minutes. Two hundred
microliters of PRP were transferred to aggregation
cuvettes with stir bars. One-centimeter pieces of
guidewires with (Adenowire) and without adenosine
(Control) were added to the cuvette and incubated
in a multiple-channel optical aggregometer (ChronoLog Corp, Hovertown, PA) and stirred for 20 minutes. Two commercially available guidewires, BMW
(Abbott Vascular, Santa Clara, CA) and Runthrough
NS (Terumo, Tokyo, Japan), were also evaluated.
Following incubation, PRP was transferred to fresh
cuvettes with stir bars and aggregation was initiated
by adding 2 µmol/L ADP or 1 µg/mL collagen and
monitored for 6 minutes. Aggregation, using plateletpoor plasma as a control reference, was assessed
by the aggregometer software. Area under the aggregation curve, maximum aggregation, slope of the
aggregation curve, and the lag time between adding
the agonist and onset of aggregation were the variables included in the analysis.

Statistical Analysis
Data are expressed as mean and SEM. Statistical
analyses of the effects of Adenowires on heart rate;
systolic, diastolic, and mean blood pressures; and
CFV in porcine experiments (n=8) were conducted on
data that were transformed by the Box-Cox method
so as to meet the assumptions of ANOVA. In this regard, assumptions of normality of groups and equality of variances among groups were tested using
NCSS 2019 Statistical Software (Kaysville, UT;, ncss.
com/software/ncss). Box-Cox transformed porcine
data were subjected to ANOVA for repeated measures (RM 1-Factor ANOVA) followed by the Bonferroni
test (versus control) using NCSS 2019 Statistical
Software. This multiple comparison test adjusts
the comparison-wise error rate, (c), in such a way
that the experiment-wise error rate, alpha(f), is kept
at a predetermined level of P<0.05. With k means,
there are k−1 comparisons with a control. Hence
alpha(c)=alpha(f)/(2(k−1)). Sample size was based on
our previous study in which we infused adenosine
into the coronary artery of closed-chest dogs and
obtained significant results with a sample size of 8.22
R2 values were calculated by Prism version 8.4.3 for
Windows (GraphPad Software, San Diego, CA; www.
graphpad.com). R2 is computed from the sum of the
squares (SS) of the distances of the points from the
best-fit curve determined by nonlinear regression
(SSreg). SSreg is normalized to SS of the distances of
the points from a horizontal line through the mean of
all Y values (SStot). R2 is calculated using the following
equation: R2=1.0−(SSresiduals/SStotal).
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RESULTS
In Vitro Adenosine-Elution Study
The cumulative elution of adenosine from 6 guidewires
over 60 minutes is illustrated for each individual guidewire in Figure 6. Figure 7 depicts the cumulative average release from the composite of all 6 guidewires, with
results expressed as either absolute release (top panel)
or relative release (percentage of 60-minute time point;
bottom panel). As shown, the release of adenosine was
curvilinear with ≈60% released in the first 20 minutes

and most of the remainder by 40 minutes. This release
profile is optimal for a typical coronary interventional procedure, with the initial burst treating and the sustained
release preventing NRF. The total amount of released
adenosine was 2.7±0.2 mg/10-cm length of wire.

Effect of Adenosine-Releasing Guidewire
on Basal Coronary Flow in the Pig
The effect of 8 guidewires on CFV in the circumflex
coronary artery and LAD is shown in Figure 8A. CFV

Downloaded from http://ahajournals.org by on September 30, 2021
Figure 6. Line graphs demonstrate the elution profile of adenosine from 6 adenosine-loaded
guidewires (Adenowires) in vitro.
The release was curvilinear over ≈60 minutes, a time frame which is ideal for an interventional procedure.
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Figure 7. Line graphs depict the average elution profile
from the 6 adenosine-loaded guidewires shown in Figure 6.
The results are plotted either as cumulative release of absolute amounts
of adenosine (top panel) or as % release relative to the 60-minute
time point (bottom panel). The average release at 60 minutes was
2.7±0.2 mg per 10 cm of length. Values are means±SEM.

increased within 1 minute of guidewire insertion and
remained significantly elevated above baseline for
27 minutes. This increase in CFV closely paralleled the
adenosine-release profile in vitro. The fold increase in
CFV (Figure 8B), a measure of coronary flow reserve,
peaked at 2.5 and remained >2.0 for 15 minutes after
wire insertion. Previous studies in our laboratory showed
that a continuous infusion of adenosine into the LAD at
50 µg/kg per minute increased CFV ≈250%. Insertion
of adenosine-releasing guidewires did not affect either mean arterial blood pressure (Figure 8C) or heart
rate (Figure 8D), and no animal developed heart block.
Coronary angiography after each guidewire removal
showed normal flow and no filling defects (Figure 9).

Effect of Adenosine-Releasing Guidewire
on Acetylcholine-Induced Coronary
Vasoconstriction in the Pig
Figure 10 summarizes the results of 3 experiments in
which acetylcholine was infused into the coronary artery to induce coronary vasoconstriction, and then an
adenosine-releasing guidewire was inserted. In the first
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experiment of this type (Figure 10A and 10B), coronary
vasoconstriction was so intense that coronary flow
ceased and the animal rapidly developed ventricular fibrillation. The heart was immediately defibrillated
and an adenosine-releasing wire was inserted into the
coronary artery. Despite continuing the acetylcholine,
immediately upon insertion of the adenosine-releasing
wire, CFV not only was restored but more than doubled from pre-acetylcholine baseline. CFV gradually
returned to baseline and the acetylcholine infusion was
stopped, and then the guidewire was removed. In 2
similar experiments (Figure 10C through 10F), insertion
of the adenosine-releasing guidewire immediately reversed acetylcholine-induced coronary vasoconstriction and maintained CFV either above or near baseline
during the acetylcholine infusion. Together, Figures
11 and 12 summarize the results of 5 experiments in
which an adenosine-releasing guidewire was inserted
before infusing acetylcholine into the coronary artery.
As shown, in all experiments, insertion of the guidewire
increased CFV and maintained CFV above baseline
even when acetylcholine was infused. The experiment in Figure 12C was particularly striking. Here, the
adenosine-releasing guidewire elevated CFV above
baseline even while acetylcholine was infused. While
maintaining the acetylcholine infusion, the guidewire
was removed, and CFV rapidly began to fall nearly to
zero. Coronary angiography in 2 animals showed acute
NRF, with restoration of coronary patency after insertion of an adenosine-releasing guidewire (Figure 13).

Evaluation of Guidewire and Coating
Performance
Light microscopy of unused wires (Figure 1) demonstrated that the hydrogel-drug coating filled the coil
spaces and provided a smooth and thin coating on
the outer coil surface. Track forces were obtained
on 4 Adenowires and 3 predicated hydrophilic wires
(Prowater; Asahi-Intecc, Justin, CA). Note that the
frictional forces to deliver and retract the Adenowires
were similar to the commercial wires indicative of similar lubricity properties (Figure 14). Light microscopy
after track tests and hydration revealed that the coating integrity remained unchanged, with no evidence of
swelling or coating loss.

Platelet Aggregation
Because a 1-cm length of an Adenowire contains
≈0.27 mg of adenosine, the concentration of adenosine present in the 0.2 mL of PRP would be estimated
to be 5 mmol/L assuming total release of adenosine
(0.27 mg/0.2 mL=1350 mg/L=5 mmol/L). Thus, there
should be a sufficient concentration of adenosine to
attenuate platelet activation. Figure 15 illustrates the
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Figure 8. Line graphs summarize the effects on coronary flow velocity (CFV) of adenosinereleasing guidewires (n=8) inserted into the LAD or circumflex coronary artery of Yucatan minipigs.
Coronary flow velocity (A) was markedly increased immediately upon wire insertion and remained
significantly elevated for 33 minutes. B, The fold increase in CFV, which equates to coronary flow
reserve. The coronary flow reserve was >2.0 for the first 15 minutes. The small spike in CFV when the
guidewire was removed was likely attributable to an incremental surge in adenosine release caused by
wire manipulation. The adenosine-releasing wire did not affect mean blood pressure (MABP) or heart rate
(C and D, respectively). Values are means and SEMs. RM 1-Factor ANOVA indicates repeated measures
1-factor analysis of variance. Bonferroni indicates Bonferroni test for comparisons to baseline (control) of
subsequent time points after insertion of the Adenowire.

effects of Adenowires and Control wires (wires coated
with the novel coating formulation but without adenosine) on area under the aggregation curve, maximum
aggregation, rate of aggregation (slope), and lag time
between addition of agonist and the onset of aggregation. Note that coated wires containing adenosine
(Adenowires) resulted in a striking inhibition of ADPinduced and collagen-induced platelet aggregation as
assessed by the reduction in area under the aggregation curve, maximum aggregation, and rate of aggregation. In addition, Adenowires delayed aggregation
in response to collagen. Unexpectedly, Control wires
exerted antiplatelet effects that were similar to, but not
quite as striking as, Adenowires. Moreover, Control
wires exerted more efficacious platelet inhibition compared with 2 commercially available hydrophilic wires
(area under the aggregation curve: Control wires,
116±30 versus commercial wires, 258±32, P<0.05;

maximum aggregation: Control wires, 28±6 versus
commercial wires, 62±8; P<0.05).

DISCUSSION
Guidewires are the first mandatory device placed in
the culprit vessel before any interventional procedure.
Current guidewires are coated with inert hydrophilic
compounds such as PVP, polyacrylamides, and hyaluronic acid to enhance the lubricity and trackability. Here,
we developed a platform guidewire to deliver adenosine
without dissolution or disruption of the coating.
Our design employed a unique guidewire microstructure and a novel combination of coating technologies, as well as jet-milled adenosine. Since no data exist
regarding formulations for drug-eluting guidewires, we
developed a matrix (reservoir) system employing an
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Figure 9. Coronary angiogram of circumflex in left anterior oblique projection.
A, Baseline; (B) adenosine guidewire positioned in distal vessel with radio-opaque tip (solid red arrow)
clearly visible; (C) post wire removal after 30 minutes showing normal flow. Also shown (dashed yellow
arrow) is the doppler Combowire used to measure coronary flow velocity.
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inner drug-containing layer and an outer barrier layer.
PVA has been used in other applications because it
is nontoxic, noncarcinogenic, bioadhesive, and elastic.23,24 The crystalline nature of PVA allows physical
cross-linking by repeated cycles of freezing and thawing with pore size altered by the number of cycles and
molecular weight.23 As cross-linking is not stable, our
group developed the concept that the addition of PVP
would stabilize the hydrogel network through hydrogen bonding between carbonyl groups of PVP and
hydroxyl groups of PVA.25 In preliminary studies, we
established that a PVA:PVP ratio of 99:1 provides both
optimal mechanical stability and the best elution profile
and was therefore used as the formulation for the inner
drug layer of the coating.
Jet milling of adenosine was required to reduce
the solid-phase particle size to obtain a smooth, lubricious coating. To optimize drug release for a typical PCI procedure, we determined that the addition
of PVAc, a more hydrophobic polymer, was required
for the barrier layer. PVAc is commercially available as
a 30% dispersion that includes sodium lauryl sulfate
as a wetting solution (Kollicoat; BASF, Florham, NJ,
USA).26 Following numerous trials, we determined that
a ratio of PVAc:PVA of 3:1 in the outer barrier layer resulted in an optimal release profile. Light and scanning
electron microscopy showed a smooth surface with a
thin outer coating diameter of a few microns. Bench
testing examined lubricity, durability, and integrity and
determined that these important parameters met Food
and Drug Administration standards. Also, in preliminary tests we found that electron-beam sterilization of
the adenosine-releasing wires did not affect release
kinetics.
In vitro studies demonstrated a curvilinear elution
of adenosine over 60 minutes with a drug load of
2.7±0.2 mg per 10 cm of wire length. Porcine studies confirmed a robust pharmacologic effect with
an immediate and significant increase in CFV for

30 minutes. The percentage increase in velocity, an
estimate of coronary flow reserve, was 2.5 during the
first 10 minutes of insertion, which is comparable to
a 50 µg/kg per minute intracoronary infusion of adenosine in this model (M.B. Forman, unpublished data,
2018). Further studies using intracoronary infusions
of acetylcholine to induce severe vasoconstriction of
the microvasculature demonstrated that insertion of
the adenosine-releasing guidewire both prevented
and reversed the acetylcholine-induced decreases in
CFV. The efficacy of the adenosine-releasing guidewire to immediately restore normal coronary perfusion was illustrated in 1 animal that developed acute
NRF and severe ischemia, which was immediately
reversed after wire insertion.
Since only a 5- to 6-cm length of guidewire could
be placed in the pig coronary arteries, it is probable
that the coronary vasodilatory response would be even
greater in humans because human coronary arteries
would accommodate at least 9 cm of the guidewire.
Adenowire insertion into pig coronary arteries did not
cause systemic hemodynamic effects, arrhythmias, or
heart block. Nonetheless, because Adenowires likely
would deliver more adenosine to patients because
of the greater length of wire in the coronary arteries,
going forward it will be important to carefully examine
the effects of Adenowires on hemodynamics and arrhythmias in patients before manipulations, when contrast medium is injected, and when a stent or balloon
is used in an actual PCI.
Platelets play a key role in MVO through release
of potent vasoconstrictor substances such as serotonin, thromboxane A2, and platelet-activating factor.
Adenosine, through activation of high-affinity A2A receptors, markedly inhibits platelet aggregation. Not surprisingly, in vitro studies demonstrated that Adenowires
significantly inhibited platelet aggregation. However,
we did not expect that the naïve coating alone, without adenosine, would also exert antiplatelet effects
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Figure 10. Line graphs summarize 3 experiments in which acetylcholine was infused into the
coronary artery before the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); experiment 2 in (C and D); and experiment 3 in (E and F). Coronary
flow velocities (CFV) are illustrated in (A, C, and E) and associated mean arterial blood pressures (MABPs)
are shown in (B, D, and F). In experiment 1, the animal developed severe ischemia that induced ventricular
fibrillation requiring cardioversion. In all 3 experiments, acetylcholine caused coronary vasoconstriction
that was reversed by insertion of the adenosine-releasing guidewire.

when compared with commercial hydrophilic wires.
Since coadministration of A2A agonists enhances the
antiplatelet effects of P2Y12 antagonists, Adenowires
could provide additional benefits to reduce thrombus
formation and embolization during PCI in clinical settings with large thrombus formation.27
MVO and NRF remain important obstacles that
frustrate achievement of optimal tissue perfusion after PCI. All patients, irrespective of clinical

presentation, are at risk for NRF, which occurs in
4% to 8% of elective procedures.4,5 However, NRF
is most prevalent in the setting of STEMI. In this
regard, NRF manifests in >50% of patients with
STEMI with anterior infarctions.4,5,28 MVO is associated with larger infarct size, abnormal ventricular
remodeling, arrhythmias, and CHF.4,5,28 Moreover,
MVO is an independent risk factor for major cardiovascular events with greater predictive power than
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Figure 11. Line graphs summarize 3 experiments in which acetylcholine was infused into the
coronary artery after the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); experiment 2 in (C and D); and experiment 3 in (E and F).
Coronary flow velocities (CFVs) are illustrated in (A, C, and E) and associated mean arterial blood
pressures (MABPs) are shown in (B, D, and F). In all 3 experiments, insertion of the adenosine-releasing
guidewire immediately increased CFV and prevented acetylcholine from reducing CFV below baseline.

ejection fraction or infarct size.6,7,29 The mechanisms
responsible for MVO are complex and include embolization by atheromatous and thrombotic debris,
release of potent vasoconstrictors, and activation
of the immune system resulting in leukocyte plugging and endothelial disruption of microvessels.3–5
The realization that prevention and prompt reversal

of MVO is paramount to improve outcomes in highrisk PCI procedures has motivated the evaluation
of numerous devices to ameliorate MVO. Various
mechanical devices that induce thrombectomy, aspirate clots, or protect against emboli have failed to
consistently reduce MVO, infarct size, or mortality,
suggesting that they are not protective throughout
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Figure 12. Line graphs summarize 2 additional experiments in which acetylcholine was infused
into the coronary artery after the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); and experiment 2 in (C and D). Coronary flow velocities (CFVs)
are illustrated in (A and C) and associated mean arterial blood pressures (MABPs) are shown in (B and
D). In both experiments, insertion of the adenosine-releasing guidewire immediately increased CFV and
prevented acetylcholine from reducing CFV below baseline. Note that in (C) removal of the adenosinereleasing guidewire while maintaining the intracoronary infusion of acetylcholine resulted in a rapid and
profound decline in CFV.

the whole procedure and do not affect humoral
factors and cytotoxic compounds responsible for
MVO.9–12

Given the negative impact of inadequate tissue perfusion with PCI, there is increased awareness of the
need for new pharmacologic approaches to prevent

Figure 13. Coronary angiography showing an example of the no-reflow phenomenon (NRF) reversed by an adenosinereleasing guidewire.
A, A baseline angiogram was obtained with the Combowire (dashed yellow arrow) in the proximal LAD. B, Soon after administration of
acetylcholine, severe NRF occurred with total cessation of blood flow in the proximal LAD (solid red arrow). C, Upon placement of an
adenosine-releasing guidewire (solid purple arrow) in the LAD, coronary flow was rapidly restored and maintained even while infusing
acetylcholine for an additional 20 minutes. D, After stopping acetylcholine and removing the guidewire, a final angiogram showed that
normal coronary flow was maintained.
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Figure 14. Track forces (g) of 4 Adenowires and 3 commercial wires with a proprietary hydrophilic
coating is illustrated.
Note that the insertion and withdrawal forces were similar, which was indicative of comparable lubricity
properties.
Downloaded from http://ahajournals.org by on September 30, 2021

and reverse MVO. Adenosine is an endogenous nucleoside that activates 4 well-characterized receptors,
producing a myriad of physiological effects that maintain microcirculatory flow.4,5,30 These include potent
vasodilatory, antiplatelet, and anti-inflammatory actions, restoration of profibrinolytic activity of endothelial
cells, acceleration of vascular healing (vasculogenesis),
and stimulation of new vessel formation (angiogenesis).4,5,31 Adenosine also functions as an endogenous
cardioprotective agent as established by the fact that
adenosine is the mediator of pre- and postconditioning.5 Activation of adenosine receptors stimulates survival kinases, which prevent opening of mitochondrial
permeability transition pores.5 These actions, in association with adenosine’s antiapoptotic effects, prevent
lethal myocyte injury. Indeed, in the acute myocardial
infarction study of adenosine trial, a 3-hour intravenous infusion of adenosine significantly reduced infarct
size in patients with anterior STEMI, and intracoronary or repeated boli of adenosine reduced MVO in
STEMI and saphenous vein grafts.5,27,32–35 The multiple
mechanisms whereby adenosine attenuates MVO and
cellular injury, which have been verified in numerous
clinical studies, indicate that adenosine is superior to
other pharmacologic agents for preventing and treating MVO.

In humans, adenosine has a plasma half-life of
only ≈1 second. Despite the potential therapeutic
benefits of adenosine in STEMI, the short half-life of
adenosine is problematic because it mandates that
adenosine be delivered by continuous administration to optimize its beneficial effects on MVO and
infarct size. Moreover, intravenously administered
adenosine induces unpleasant, and in some cases
serious, side effects. Thus, there is a dire need to
develop a convenient system that allows continuous
delivery of adenosine in pharmacologic amounts
directly into the coronary circulation while avoiding
adverse effects. Since guidewires are the first mandatory device placed in the culprit vessel before PCI,
an adenosine-releasing guidewire provides for an
autonomous system that performs without thought
or planning. In this regard, our adenosine-releasing
guidewire is a platform guidewire product coated
with a novel hydrophilic coating that allows delivery of
a drug, without disruption of the coating, throughout
the interventional procedure. This guidewire achieves
high concentrations of adenosine at the target site,
thereby optimizing pharmacologic efficacy yet avoiding side effects that would be induced with high-dose
systemic administration. Moreover, since adenosine release is immediate, our adenosine-releasing
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Figure 15. Effects of Adenowires and Control wires (wires coated with the novel coating formulation but without adenosine)
on area under the aggregation curve (AUC), maximum aggregation, rate of aggregation (slope) and lag time between addition
of agonist and the onset of aggregation.
A, Representative platelet aggregation tracings showing aggregation responses to ADP (2 µmol/L), collagen (1 µg/mL), ADP+Adenowire,
collagen+Adenowire, ADP+Control wire and collagen+Control wire. Adenowires were coated with our novel hydrophilic coating
that contained adenosine; Control wires were similarly coated but did not contain adenosine. Bar graphs summarize the effects of
treatments on (B) area under the aggregation curve, (C) maximum aggregation, (D) slope of the aggregation curve and (E) the lag
time between adding the agonist and onset of aggregation. Note that Adenowires markedly inhibited platelet aggregation. The inert
coating also manifested antiplatelet properties that was similar to, but not quite as efficacious as, Adenowires. Data were analyzed by
1-factor ANOVA after Box-Cox transformation. *Significantly different vs agonist without wire; †Significantly different vs corresponding
Control wire.

guidewire would promote preconditioning in patients
with STEMI before reperfusion of the myocardium
following balloon or stent placement.
In conclusion, here we describe a therapeutic
agent–releasing guidewire platform that allows for
continuous release of pharmacologic amounts of adenosine directly into the microvasculature during a
PCI procedure. The average time for the total PCI procedure is ≈60 minutes from start to finish. However,
once the guide catheter has been positioned in the
coronary ostium, guidewire insertion into the culprit
vessel for placement of balloon and stent catheters
rarely exceeds 30 minutes, even with complex lesions
and acute coronary occlusions; thus, the current design of the Adenowire allows for the appropriate time
frame for release of pharmacologic amounts of adenosine. In the present study, there was a small spike
in CFV when the guidewire was removed; this was
likely attributable to an incremental surge in adenosine release caused by wire manipulation. If this occurs
in the human coronary circulation during balloon and
stent insertion, it would be beneficial since a surge
of adenosine during these critical moments would be

advantageous. The portion of the Adenowire in the
guide catheter would also elute adenosine, and thus
extra adenosine would be delivered with injection of
contrast material; this design is also a plus. The development of this guidewire necessitated optimization
of the surface area of the guidewire, use of novel hydrophilic and hydrophobic polymers, and creation of
a reservoir (matrix) system comprising an inner drug
layer and outer barrier layer. In vitro studies confirmed
an ideal elution profile for adenosine that was verified in a large animal model where robust coronary
vasodilatation and rapid reversal of vasoconstriction
was demonstrated. Bench studies revealed that wire
performance and coating quality (lubricity, durability, adhesion, and integrity) were comparable to inert
hydrophilic guidewires. The novel inert coating also
provides antiplatelet effects that were amplified with
the addition of adenosine in the coating. Although
we have not yet performed biocompatibility testing,
the safety of PVA and PVAc is well established, as
they are used as tissue replacement material and in
drug and food products.23–26 This technology could
be used on a pressure wire to measure fractional flow
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reserve, thereby avoiding the side effects of large intravenous infusions of adenosine. The coating formulation would also be applicable for controlled release
of other drugs for interventional procedures such as
anti-thrombotic and anti-platelet agents, anticoagulants and antimitotic agents. Furthermore, the process could be employed to coat other devices such
as vascular sheaths, catheters, balloons, and stents.
While the overall incidence of NRF is low (4%–8%),
NRF remains prevalent in high-risk patients undergoing procedures such as anterior STEMI and saphenous
vein graft interventions. Furthermore, all patients, irrespective of a clinical presentation, are at risk. Since
an Adenowire would add little to the overall cost of a
procedure and since NRF is unpredictable, likely the
cost-benefit ratio is favorable for use of the Adenowire
as insurance against NRF.
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